Navigation Links
Arthrosurface® Hits the 20,000 Implant Milestone

FRANKLIN, Mass., May 24 /PRNewswire/ -- Arthrosurface, Inc. (, the developer of inlay joint resurfacing systems, announced the achievement of a significant clinical milestone.  Over 20,000 patients, typically middle aged, have been treated with the various Arthrosurface cartilage resurfacing systems, with the early patients now 6 years post surgery.

"Back in 2003, there was no accepted surgical 'next step' for those patients that had exhausted conservative & biological therapies such as drug injections & microfracture.  With the passing of the 20,000 patient milestone and with more than 98% of the implants still in place, we have achieved our initial goal of providing a less invasive option that would allow patients to go back to an active lifestyle while delaying the need for a joint replacement," commented Steven Ek, COO.

"For very advanced disease in the older aged patient, joint replacement still provides a good option.  However, the baby boomer population has been the silent sufferer.  They have joint pain, limited mobility and all the signs of early articular cartilage damage. In my opinion, a well accepted treatment for early disease in the boomer population does not exist.  Having the Arthrosurface technology as an interim treatment has provided a great new option for these patients," remarked Anthony Schepsis, MD, Professor of Orthopaedic Surgery at Boston University.  "For me and thousands of other surgeons, this system has been a very effective solution for those patients that have failed early treatments and yet are too young for a total joint replacement. The Arthrosurface system has filled this gap in my sports medicine practice."

The Arthrosurface inlay resurfacing technology was developed to treat the young and active patient typically referred to as the baby boomer.  The company's technology uses a family of implants with different shapes and sizes to effectively recreate the patient's joint geometry with an intraoperative 3D mapping instrument set.  Arthrosurface has been a leader in introducing anatomic inlay resurfacing in the knee, shoulder and toe.  The company's focus remains dedicated to early joint resurfacing for the boomer population. The company's systems are indicated and FDA cleared for use in the knee, shoulder, hip and toe.

SOURCE Arthrosurface, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
2. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
3. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
4. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
5. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
7. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
10. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
11. First Human Implant of New Archus Orthopedics Facet Replacement System
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... A simply groundbreaking television series, "Voices in America", which ... into an array of issues that are presently affecting Americans. Dedicated to providing the ... show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... in central Michigan, have come together on Thanksgiving Day to share the things ... for viewing on the Serenity Point YouTube channel, patients displayed what they wrote ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
Breaking Medicine News(10 mins):